Previous Close | 16.84 |
Open | 16.72 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 16.60 - 17.04 |
52 Week Range | 12.45 - 21.01 |
Volume | 14,996 |
Avg. Volume | 127,036 |
Market Cap | 380.841M |
Beta | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.22 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 24.75 |
Detailed Characterization of Unique DolaLock Technology Enhancements to Drug Efficacy and Tolerability. XMT-1522 Demonstrates Synergy in Combination with a Checkpoint Inhibitor. CAMBRIDGE, Mass., April ...
CAMBRIDGE, Mass., April 09, 2018-- Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates based on its Dolaflexin ...
Mersana Therapeutics Inc’s (NASDAQ:MRSN): Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The US$374.22M market-cap company announcedRead More...
Enrollment on Track for Phase 1 Trial of XMT-1522 Patients with Advanced Tumors Expressing HER2. Progressing Phase 1 Trial of XMT-1536, First-in-Class Dolaflexin ® Antibody Drug Conjugate Targeting NaPi2b. ...
Assessing Mersana Therapeutics Inc’s (NASDAQ:MRSN) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met orRead More...
CAMBRIDGE, Mass., March 21, 2018-- Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates based on its Dolaflexin ...
JPMorgan is generally bullish on biotech and in most cases sees opportunity for longer-term upside, but its ratings strategy dictates the sidelining of lower conviction stocks. Here's a look at biotech ...
CAMBRIDGE, Mass., March 19, 2018-- Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates based on its proprietary ...
CAMBRIDGE, Mass., March 12, 2018-- Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates based on its Dolaflexin ...
Mersana Therapeutics (MRSN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
CAMBRIDGE, Mass., Feb. 07, 2018-- Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates based on its Dolaflexin ...
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Mersana Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
In September 2017, Mersana Therapeutics Inc (NASDAQ:MRSN) released its most recent earnings update. Generally, analyst consensus outlook seem bearish, with earnings expected to decline by -98.33% in the upcoming year.Read More...
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Mersana Therapeutics, Inc. a score of 75. Our analysis is based on comparing Mersana Therapeutics, Inc. with the following peers – Protagonist Therapeutics, Inc., Parallax Health Sciences Inc., Plandai Biotechnology, Inc. and Pieris Pharmaceuticals, Inc. (PTGX-US, PRLX-US, PLPL-US and PIRS-US). Investment Outlook Mersana Therapeutics, Inc. has a ... Read more (Read more...)
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Mersana Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
Mersana Therapeutics has accomplished a lot in recent years. The Cambridge biotech signed collaboration deals with drug giants Takeda and Merck KGaA, released promising data on its experimental cancer treatments, and recently raised $75 million in an initial public offering. The company’s chief business officer, Eva Jack, participates in Canine Companions for Independence, a nonprofit program in which volunteer “puppy raisers” like her provide homes for aspiring service dogs before they are placed with children, adults and veterans with disabilities.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Mersana Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
A 9-year-old biotech company headquartered in Boston’s Back Bay, Rhythm Pharmaceuticals Inc. has become the fourth local drugmaker to go public this year, raising $120 million in an upsized public offering. Rhythm, which has 15 employees based in a 6,830-square-foot office at 500 Boylston St., sold 7 million shares for $17 each, beating the range it floated in a federal filing just a couple weeks ago of $14-$16. It’s the second-biggest IPO for a Boston-area biotech in what’s so far a slow year, with only Cambridge-based Akcea Therapeutics (AKCA) raising more, with a $144 million IPO in July .
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Mersana Therapeutics, Inc. a score of 69. Our analysis is based on comparing Mersana Therapeutics, Inc. with the following peers – Pieris Pharmaceuticals, Inc., PDL BioPharma, Inc., Bioblast Pharma Ltd. and InVivo Therapeutics Corporation (PIRS-US, PDLI-US, ORPN-US and NVIV-US). Investment Outlook Mersana Therapeutics, Inc. has a fundamental ... Read more (Read more...)